专利号:US-9066864-B2 优先权日:2011-01-12 标 题:Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions 发明人:NIEDERMANN HANS PETER; BOTHE HEIKO 权利人:NIEDERMANN HANS PETER; BOTHE HEIKO; INTERVET INC 摘要:Disclosed is a method of making particles of a drug wherein use is made of diafiltration. The diafiltration can be with anti-solvent, in which case a precipitate is obtained of particles as such. The diafiltration can also be with a pharmaceutically acceptable suspension medium. In that case several process steps of isolating, drying, transporting of particles can be avoided, because the suspension resulting from the synthesis of the particles is directly turned into a final drug product formulation.
专利号:US-2009111737-A1 优先权日:1999-05-24 标题:Novel antibacterial agents 发明人:CHRISTENSEN BURTON G; MORAN EDMUND J; GRIFFIN JOHN H; JUDICE J KEVIN; MU YONGQI; PACE JOHN L; MAMMEN MATHAI; AGGEN JAMES 权利人:CHRISTENSEN BURTON G; MORAN EDMUND J; GRIFFIN JOHN H; JUDICE J KEVIN; MU YONGQI; PACE JOHN L; MAMMEN MATHAI; AGGEN JAMES 摘要:This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands in their monovalent (i.e., unlinked) state have the ability to bind to a an enzyme involved in cell wall biosynthesis and metabolism, a precursor used in the synthesis of the bacterial cell wall and/or the bacterial cell surface thereby interfere with the synthesis and/or metabolism of the cell wall. In particular the multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands hasn a ligand domain capable of binding to penicillin binding proteins, a transpeptidase enzyme, a substrate of a transpeptidase enzyme, a beta-lactamase enzyme, pencillinase enzyme, cephalosporinase enzyme, a transglycoslase enzyme, or a transglycosylase enzyme substrate; Preferably, the ligands are selected from the beta lactam or glycopeptide class of antibacterial agents.
专利号:US-2011015119-A1 优先权日:2009-06-24 标题:Novel semi-synthetic glycopeptides as antibacterial agents 发明人:CHU DANIEL; YE TAO; WANG BING 权利人:LEAD THERAPEUTICS INC 摘要:Semi-synthetic glycopeptides having antibacterial activity are described, in particular, the semi-synthetic glycopeptides described herein are made by chemical modification of a glycopeptide (Compound A, Compound B, Compound H or Compound C) or monosaccharide made by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium to give the amino acid-4 monosaccharide; conversion of the monosaccharide to the amino-sugar derivative; acylation of the amino substituent on the amino acid-4 amino-substituted sugar moiety on these scaffolds with certain acyl groups; and conversion of the acid moiety on the macrocyclic ring of these scaffolds to certain substituted amides. Key reaction is the treatment of properly protected intermediate compound with isocyanate. Also provided are methods for the synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections.
专利号:NZ-505979-A 优先权日:1998-06-08 标 题 :Multibinding antibacterial agents comprising 2 antibiotic or aglycone ligands, connected by a linker, capable of affecting cell wall synthesis or metabolism
1: Watanabe NA, Katsu K. Cefclidin (E1040), a novel cephalosporin: lack of selection of beta-lactamase overproducing mutants in an in vitro pharmacokinetic model system. J Antibiot (Tokyo). 1992 Aug;45(8):1335-45. doi: 10.7164/antibiotics.45.1335. 30(5):633-41. doi: 10.1093/jac/30.5.633. 30(4):475-87. doi: 10.1093/jac/30.4.475. 38(4):507-10. Japanese. 45(9):1526-32. doi: 10.7164/antibiotics.45.1526. 40(8):689-94. 46(1):18-30. 19(9):534-6. doi: 10.1111/j.1346-8138.1992.tb03724.x. 45(5):512-22. Japanese. 36(12):2595-601. doi: 10.1128/aac.36.12.2595.
合成参考文献
参考文献:10.1093/jac/30.5.633 摘要:Watanabe N, Hiruma R, Katsu K. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 1992 Nov;30(5):633–41. doi: 10.1093/jac/30.5.633. 参考文献:10.1128/aac.36.7.1580 摘要:Satoh M, Munakata K, Takeuchi H, Yoshida O. Evaluation of the Usefulness of a Novel Injectable Cephalosporin, E1040, and Ceftazidime for Management of Complicated Urinary Tract Infections Caused by Pseudomonas aeruginosa and Proteus mirabilis by Using the Rat Urolithiasis Model. Antimicrob Agents Chemother. 1992 Jul;36(7):1580–3. doi: 10.1128/aac.36.7.1580. 摘要:Tatsumi N, Im T, Furukawa Y, Sannomiya Y, Inoue K, Kageyama T, Ohyabu H, Akasaka K, Nasu K, Yonezawa T. [Therapeutic effects of cefclidin against severe infections in patients with hematopoietic disorders. Hanshin Infection Study Group]. Jpn J Antibiot. 1992 May;45(5):512–22. 摘要:Watanabe N, Asakawa N, Toyosawa T, Hiruma R, Hata K, Ueno J, Katsu K, Yoshida Y. [Effect of cefclidin and E1077, new cephalosporins, on the alcohol-metabolizing system in rats]. Jpn J Antibiot. 1992 Apr;45(4):364–70. 参考文献:10.2165/00003495-199447030-00007 摘要:Barradell LB, Bryson HM. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994 Mar;47(3):471–505. doi: 10.2165/00003495-199447030-00007.